Clinical Trials Directory

Trials / Completed

CompletedNCT02667938

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
510 (actual)
Sponsor
Hanmi Pharmaceutical Company Limited · Industry
Sex
Male
Age
50 Years
Healthy volunteers
Not accepted

Summary

The main objective of this study is to evaluate efficacy and safety of HCP1301 capsule in patients with Benign Prostatic Hyperplasia and Erectile Dysfunction

Detailed description

A multicenter, randomized, double-blind, phase 3 clinical trial to evaluate the efficacy and safety of HCP1303 capsule

Conditions

Interventions

TypeNameDescription
DRUGHCP1303 capsule 5/0.2mg
DRUGHCP1303 capsule 5/0.4mg
DRUGHGP1201
DRUGHCP1303 capsule 5/0.2mg placebo
DRUGHCP1303 capsule 5/0.4mg placebo
DRUGHGP1201 placebo

Timeline

Start date
2015-03-01
Primary completion
2016-01-01
Completion
2016-05-01
First posted
2016-01-29
Last updated
2016-10-13

Source: ClinicalTrials.gov record NCT02667938. Inclusion in this directory is not an endorsement.